Germline mutations in the BRCA1 tumour suppressor gene on chromosome 17q21 are responsible for approximately half of the cases of hereditary breast cancer, including the majority of familial breast/ovarian cancers. To increase our knowledge of the spectrum of BRCA1 mutations, we have extended our analysis to include patients with varied family histories of cancer ofthe breast, ovary, and at multiple other sites. We have analysed 23 unrelated familial cases using direct sequencing or a combination of dideoxy fingerprinting and sequencing procedures. Twenty one of these families contained three or more cases of breast or ovarian cancer and two families had one case of breast cancer diagnosed before the age of 40 and one case of ovarian cancer. The common frameshift mutation 5382insC was detected in two patients, and the 185delAG mutation was found in a family of Ashkenazi Jewish descent. The novel frameshift mutation 3450del4 (CAAG) was detected in a patient who developed breast cancer at the age of 28 and ovarian cancer at the age of 34. Three other women in this family were diagnosed with breast cancer at the ages of 26, 29, and 40. The novel frameshift mutation 2953del3+C was found in a French Canadian woman who had developed two primary cancers of the breast at the age of 37 and 38 and renal cancer at the age of 38.
Abstract
Germline mutations in the BRCA1 tumour suppressor gene on chromosome 17q21 are responsible for approximately half of the cases of hereditary breast cancer, including the majority of familial breast/ovarian cancers. To increase our knowledge of the spectrum of BRCA1 mutations, we have extended our analysis to include patients with varied family histories of cancer ofthe breast, ovary, and at multiple other sites. We have analysed 23 unrelated familial cases using direct sequencing or a combination of dideoxy fingerprinting and sequencing procedures. Twenty one of these families contained three or more cases of breast or ovarian cancer and two families had one case of breast cancer diagnosed before the age of 40 and one case of ovarian cancer. The common frameshift mutation 5382insC was detected in two patients, and the 185delAG mutation was found in a family of Ashkenazi Jewish descent. The novel frameshift mutation 3450del4 (CAAG) was detected in a patient who developed breast cancer at the age of 28 and ovarian cancer at the age of 34. Three other women in this family were diagnosed with breast cancer at the ages of 26, 29, and 40. The novel frameshift mutation 2953del3+C was found in a French Canadian woman who had developed two primary cancers of the breast at the age of 37 and 38 26 Mutation analysis of the BRCA1 gene for women in families with a high incidence of breast/ovarian cancer is now possible.3 2728 During the course of the present study, many distinct germline mutations scattered throughout the coding region were detected with no evidence of clustering, while there is evidence suggesting a correlation between their location and the ratio of breast to ovarian cancer incidence in each family.'1'1 262729-42 Among the seven distinct mutations that we previously reported in breast/ovarian cancer families ascertained in Canada, four of them, namely 185delAG, 1294del40, 4184del4, and 5382insC, are among the most frequently reported.32 39 20 . PCR was performed using exon 2 or exon 20 primer sets under the same experimental procedures as previously described32 and the sequence of these BRCA1 exons was determined by direct sequencing of single stranded DNA produced by asymmetrical PCR as previously described. '2 In order to determine the nature of the novel frameshift mutation 3450de14 in index case No 17 from family 407, the region overlapping the mutation was amplified by PCR using the forward primer 5' CCAAGTACAGTGAG-CACAATTA 3' and the reverse primer 5' AAATGTGCTCCCAAAAGCATAAA 3' and then subcloned in the pCRII plasmid using the TA cloning kit (In Vitrogen). jmol/l of dNTPs, 0.24 gmol/l of each primer, 1.5 U Taq polymerase (Perkin Elmer Cetus), and 4 ng of genomic DNA. The reactions were carried out using a Perkin-Elmer Cetus thermal cycler. After an initial denaturation at 95°C for five minutes, the samples were first processed through five cycles consisting of 10 seconds at 95°C, 10 seconds at 62°C, and one minute at 72°C, and thereafter through 35 cycles consisting of 10 seconds at 95°C, 10 seconds at 58°C, and one minute at 72°C.
Samples were then incubated with 0.8 U of shrimp alkaline phosphatase and 2.6 U of exonuclease 1 for 30 minutes at 37°C followed by 15 minutes at 80°C and finally cooled at 4°C. The DDF reactions were then performed in a 10 Id volume using the Cyclist Taq DNA sequencing kit (Stratagene) with approximately 100 ng of PCR product, 0. In order to determine the nature of the novel frameshift mutation 2953del3+C in index case No 18 from family 290, the region overlapping the mutation was amplified by PCR using the forward primer 5' GTGTGAGTCAGTGT-GCAGCA 3' and the reverse primer 5' GCCTCTGAACTGAGATGATAGA 3' and then subcloned in the pCRII plasmid using the TA cloning kit (In Vitrogen). The sequence of the PCR fragment was completed in both orientations. The mutation was also found by direct sequencing of the asymmetrical PCR product thus excluding a cloning artefact.
GENOTYPING OF MICROSATELLITE MARKERS WITHIN OR CLOSE TO THE BRCA1 GENE
The four short tandem repeat markers D17S855, D17S1322, D17S1323, and D17S1327 were genotyped in the index cases from each family using standard procedures.32 44 Radiolabelled PCR products were electrophoresed on standard 6% polyacrylamide denaturing sequencing gels. The marker 43 44 The haplotype of the 23 probands was constructed for the same three short tandem repeat markers within the BRCA1 gene (D17S855, D17S1322, and D17S1323) and with one marker approximately 100 kb telomeric to the gene (D17S1327). 32 The D17S1327 allele 0 was detected in the probands of families 289 and 448. The frequency of this rare allele was estimated to be less than 0.0144 and has been previously detected only in patients bearing the mutation 5382insC.32 44 As predicted, both proband No 5 in family 289 and patient No 22 in family 448 were carriers of the 5382insC mutation, as shown by direct sequencing (fig 1) . Unfortunately, it was impossible to test for the presence of the 5382insC mutation in colon cancer cases No 4 and No 5 of family 448 because DNA samples were not available. Moreover, it is of interest to note that the haplotype D, E, F, M/O of the proband in family 289 is consistent with the haplotype D, E, F, 0 which is shared in 19 out of 21 subjects studied bearing the 5382insC mutation.32 44 However, the haplotype E, C/E, F, H/O detected in the index case of family 448 indicates a discrepancy at the D17S855 marker owing to the presence of the E allele, which is two base pairs shorter than the D allele. The most likely explanation for this observation is a single mutation occurring at D17S855, as previously observed in the index case of family MICH205, who has the haplotype E, D/E, F, O.44 It has been estimated that the mutation 5382insC has occurred 38 generations ago (90% limits 18-69). 44 The 185delAG mutation has been detected in several Ashkenazi Jewish breast and ovarian cancer families from Canada32 46 and other countries.18 30 41 44 289 448
3' Figure1 Detection of the frameshift mutation 5382insC in two families. PanelA: pedigrees offamilies 289 and 448. Br: breast cancer, Ov: ovarian cancer, Co: colon cancer, Psu: primary site unknown. The numbers following these abbreviations indicate age at diagnosis. The probands carrying the 5382insC mutation in these families are indicated with an arrow. The subject numbers are shown below the symbols. Panel B: the autoradiograms show only the partial nucleotide sequence obtained by direct sequencing of PCR products and corresponding amino acids of the sense strand of the BRCA 1 region including the frameshift mutation 5382insC.
Dideoxy fingerprinting coupled with direct sequencing analyses showed the presence in exon 11 of the novel frameshift mutation 2953del3+C in heterozygote No 18 in family 290. This screening method is a hybrid between single stranded conformation polymorphism (SSCP) analysis and Sanger dideoxy sequencing involving sequencing reaction with one labelled dideoxynucleotide followed by non-denaturing polyacrylamide gel electrophoresis.4 46 In addition to being more sensitive than SSCP, this method offers the opportunity to amplify larger fragments (fig 4) . (fig 3) . This peculiar novel frameshift mutation was identified in the proband who had developed breast cancer at the ages of 37 and 38 and kidney cancer at the age of 38. This mutation is the first BRCA1 mutation that we found in a French Canadian family. This mutation was not detected in her mother (No 15) and therefore, barring de novo mutation, is deduced to be of paternal origin. This hypothesis is consistent with three breast cancers in this branch of the family. It is unfortunate that we do not have any DNA sample available from additional subjects affected with cancer in this family. The maternal family history is notable for a case of male breast cancer, several female breast cancers, throat cancer, and prostate cancers. All these cancers have been associated with BRCA2. It remains possible that the proband is a carrier of a mutation in both genes; it is therefore premature to attribute the renal cancer to the BRCA1 mutation.
In the 18 families in which mutations were not detected, only five were clear examples of 
